 {#s9000}

1. Define severe community-acquired pneumonia (CAP). {#s0010}
----------------------------------------------------

*Severe community-acquired pneumonia* refers to CAP that requires management in the intensive care unit (ICU). The mortality rate for patients with severe CAP is high, and the empiric antimicrobial regimen for this subgroup differs from antibiotic coverage recommended for less severe cases of pneumonia. Ultimately, the decision to admit a patient to the ICU must be based on clinical judgment; however, various indices have been validated to predict the need for ICU admission and can supplement clinical decision-making. The modified American Thoracic Society (ATS) rules define severe CAP by the presence of either one of two major criteria (septic shock or need for mechanical ventilation) *or* two of three minor criteria (systolic blood pressure \[SBP\] ≤ 90 mmHg, multilobar pneumonia, and PaO~2~/FiO~2~ \< 250). The British Thoracic Society guidelines recommend that patients with two or more of the following be considered for ICU admission: altered mental status, blood urea nitrogen \> 19.1 mg/dL, respiratory rate ≥ 30 breaths/min, and either DBP ≤ 60 mmHg or SBP \< 90 mmHg (CURB = confusion, urea, respiratory rate, blood pressure).

2. Which pathogens most commonly cause severe CAP? {#s0020}
--------------------------------------------------

[Table 17-1](#t0010){ref-type="table"} lists the most common culprits. *Streptococcus pneumoniae* is the most frequently identified causative organism. Pathogens are identified in fewer than 50% of cases. Culturing the blood or pleural fluid in addition to respiratory tract specimens may increase the diagnostic yield. Furthermore, *Legionella pneumophila* can often result in severe illness; therefore, urinary antigen for *L. pneumophila* serogroup 1 should be measured. Whether or not a specific organism is identified does not appear to affect mortality; however, microbiologic data can be used to tailor therapy.Table 17-1Common Pathogens that Cause Severe Community-Acquired Pneumonia and Empiric Antibiotic Therapy[\*](#tn0010){ref-type="table-fn"}, [†](#tn0020){ref-type="table-fn"}OrganismsTherapy[‡](#tn0030){ref-type="table-fn"}, [∥](#tn0050){ref-type="table-fn"}**a. No risks for *Pseudomonas aeruginosa****Streptococcus pneumoniae* (including DRSP)Intravenous β-lactam (cefotaxime, ceftriaxone)[§](#tn0040){ref-type="table-fn"}*Legionella* spp.*plus eitherHemophilus influenzae*Intravenous macrolide (azithromycin)Enteric gram-negative bacilli*orStaphylococcus aureus*Intravenous fluoroquinolone*Mycoplasma pneumoniae*Respiratory virusesMiscellaneous *Chlamydia pneumonlae, Mycobacterium tuberculosis*, endemic fungi**b. Risks for *Pseudomonas aeruginosa***[∥](#tn0050){ref-type="table-fn"}All of the above pathogens plus *P. aeruginosa*Selected intrevenous antipseudomonal β-lactam (cefepime, imipenem, meropenem, piperacillin/tazobactam)[¶](#tn0060){ref-type="table-fn"}*plus* intravenous antipseudomonal quinolone (ciprofloxacin)*or*Selected intravenous antipseudomonal β-lactam (cefepime, imipenem, meropenem, piperacillin/tazobactam)[¶](#tn0060){ref-type="table-fn"}*plus* intravenous aminoglycoside*plus either*Intravenous macrolide (azithromycin)*or*Intravenous nonpseudomonal fluoroquinolone[^1][^2][^3][^4][^5][^6]Data from Niederman MS, Mandell LA, Anzueto A, et al; American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730--1754, 2001, with permission.

3. Is the sputum Gram\'s stain and culture helpful diagnostically for CAP? {#s0030}
--------------------------------------------------------------------------

Sputum Gram\'s stain and culture can be performed noninvasively and are inexpensive diagnostic tests. A sputum Gram\'s stain specimen is considered satisfactory for interpretation when the neutrophil count is \>25 per low-power field and \<10 epithelial cells. There is some controversy regarding how the results of a sputum Gram\'s stain should influence clinical practice. The ATS recommends that this test be used to broaden antibiotic therapy to treat unsuspected organisms not covered by the usual empiric regimen. Conversely, the Infectious Diseases Society of America (IDSA) guidelines suggest that empiric antimicrobial therapy be narrowed based on sputum Gram\'s stain findings. Keep in mind the diagnostic limitations of sputum Gram\'s stain and culture, including the inability to visualize atypical organisms, contamination by oral flora, and the difficulty encountered by some patients to provide adequate specimens.

4. What determines the selection of empiric antimicrobial therapy for patients with severe CAP? {#s0040}
-----------------------------------------------------------------------------------------------

The initial empiric antibiotic regimen depends on the presence of risk factors for *Pseudomonas aeruginosa*. These include malnutrition, underlying structural pulmonary disease such as bronchiectasis, \>7 days of broad-spectrum antibiotic therapy within the past month, leukopenic immunosuppression, and steroid use (\>10 mg prednisone per day). Recommended antibiotics according to the most recent ATS guidelines are listed in [Table 17-1](#t0010){ref-type="table"}. The current IDSA guidelines also note that exposure to an antibiotic within the preceding 3 months predicts resistance to that antibiotic class. Prompt administration (within 4 hours of presentation) of appropriate empiric antibiotics is strongly encouraged because studies suggest that delays in treatment are associated with worse outcomes.

5. Who is at risk for penicillin-resistant *S. pneumoniae* pneumonia, and does this affect treatment? {#s0050}
-----------------------------------------------------------------------------------------------------

Risk factors for infection due to penicillin-resistant *S. pneumoniae* include age older than 65 years, recent beta-lactam therapy, multiple comorbidities, alcoholism, immunosuppression, noninvasive disease, and contact with a child who attends day care. Several investigations indicate that penicillin-resistant *S. pneumoniae* pneumonia (in the absence of meningitis) can be successfully treated with beta-lactam antibiotics without adversely affecting mortality *unless* the minimal inhibitory concentration is ≥4 mg/L.

*S. pneumoniae* resistance against macrolides and fluoroquinolones is increasing. Clinical failures with macrolides are rare despite macrolide resistance; however, fluoroquinolones with less potency against *S. pneumoniae* are likely to be ineffective against resistant strains.

Campbell GD Jr, Silberman R: Drug-resistant *Streptococcus pneumoniae*. Clin Infect Dis 26:1188--1195, 1998.

Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al: Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant *Streptococcus pneumoniae*: A multicenter study. Clin Infect Dis 24:1052--1059, 1997.Key Points: Initial Management of Acute Pneumonia1Treat empirically if pneumonia is clinically suspected.2Select the initial empiric therapy based on the current bacteriology and resistance patterns at each institution. Alternatively, published evidence-based practice guidelines may be used.3Obtain cultures of respiratory tract specimens to identify pathogen(s), preferably before the initiation of antibiotics. However, the administration of antibiotic therapy should not be delayed for diagnostic testing.4Narrow the initial antibiotic regimen based on quantitative culture results and clinical response (i.e., de-escalation).5Avoid excessive antibiotic use by de-escalating therapy when appropriate and prescribing the minimal duration of therapy required for efficacy.

6. What is meant by "de-escalation" of antibiotic therapy? {#s0060}
----------------------------------------------------------

Antibiotic use promotes the development of antibiotic resistance; therefore, restricted use of antimicrobial drugs should be encouraged. If the patient is responding favorably, the initial empiric antibiotic regimen should be de-escalated, or narrowed to the most specific antibiotic based on the results of respiratory tract cultures and sensitivities.

7. When is it safe to switch a patient to oral therapy? {#s0070}
-------------------------------------------------------

Conversion to oral therapy may be considered in a clinically stable patient who demonstrates the following: improvement in cough and shortness of breath, defervescence (\<100°F) on two separate measurements 8 hours apart, white blood cell count trending toward normal, and satisfactory oral intake and gastrointestinal tract absorption.

8. What defines a treatment failure? {#s0080}
------------------------------------

The majority of patients receiving appropriate therapy show a favorable clinical response within 72 hours. Therefore, initial antibiotic therapy should not be changed within 72 hours of initiation unless indicated by significant clinical worsening or microbiologic data. Remember that certain host factors, such as advanced age, alcoholism, and chronic obstructive pulmonary disease (COPD), have been associated with delayed resolution despite appropriate treatment. Radiographic resolution of pneumonia lags behind clinical improvement and in some cases may take up to 8--10 weeks to clear completely.

9. Discuss the potential reasons why a patient may not respond favorably to empiric therapy. {#s0090}
--------------------------------------------------------------------------------------------

Clinical deterioration or a lack of response to empiric antimicrobial therapy within 3 days often indicates treatment failure, warranting thorough reassessment and additional investigation. The following should be considered:1Inappropriate antimicrobial therapy▪Is the dosing adequate?▪Are all potential bacterial pathogens covered by the empiric regimen?▪Are the organisms resistant, or has a previously sensitive pathogen developed resistance?▪Is the pathogen bacterial? Consider other pathogens, including viruses, endemic fungi, and mycobacteria.▪Is the host immunocompromised and at risk for opportunistic infections such as *Pneumocystis jiroveci?*▪Is the disease infectious? Has the patient been misdiagnosed (*see* [question 11](#s0120){ref-type="sec"})?2Complications of lung infection or hospitalization▪Has the patient developed a lung abscess or empyema?▪Does the patient have acute respiratory distress syndrome (ARDS)?▪Have the bacteria seeded extrapulmonary sites (e.g., endocarditis, septic arthritis, meningitis)?▪Has the patient acquired a new nosocomial infection (e.g., urinary tract infection, central line infection, sinusitis)?

10. How should a patient with nonresolving pneumonia be evaluated? {#s0100}
------------------------------------------------------------------

The clinician should review initial culture results and sensitivities and collect additional lower respiratory tract and blood cultures. Broadening empiric therapy may be indicated while awaiting the results of additional testing. All patients should have a repeat chest radiograph at this time. Additional history taking may reveal human immunodeficiency virus risk factors, tick exposure, travel history, or other diagnostic clues. Further testing, such as chest computed tomography scan or ultrasound, should be directed at the likely cause of treatment failure. If the procedure can be performed safely, a thoracentesis of a pleural effusion can exclude a complicated effusion or empyema. Bronchoscopy has good diagnostic utility, and specimens should be sent for quantitative bacterial cultures and sensitivities, as well as for stains and cultures of unusual organisms (e.g., mycobacteria, viruses, endemic fungi, and *P. jiroveci*). If the diagnosis remains elusive, a trial of corticosteroids or a thoracoscopic or open lung biopsy may be considered in the appropriate clinical setting.

Ioanas M, Ferrer M, Cavalcanti M, et al: Causes and predictors of nonresponse to treatment of intensive care unit--acquired pneumonia. Crit Care Med 32:938--945, 2004.

11. Which noninfectious processes can present with signs and symptoms of acute pneumonia? {#s0110}
-----------------------------------------------------------------------------------------

Noninfectious conditions that can mimic acute pneumonia include ARDS, traumatic pulmonary contusion, pneumonitis resulting from connective tissue disease (e.g., systemic lupus erythematosus), acute hypersensitivity pneumonitis, drug-induced pneumonitis, diffuse alveolar hemorrhage (e.g., Goodpasture\'s syndrome), Wegener\'s granulomatosis, bronchiolitis obliterans organizing pneumonia, acute interstitial pneumonia (Hamman-Rich syndrome), acute eosinophilic pneumonia, pulmonary embolism with infarction, atelectasis, chemical pneumonitis (aspiration), and malignancy (e.g., bronchoalveolar carcinoma, lymphangitic carcinomatosis, Kaposi sarcoma).

12. What about viral pneumonia? {#s0120}
-------------------------------

Viral pneumonia can be severe, particularly in elderly or immunocompromised patients or when complicated by a secondary bacterial infection, such as *S. pneumoniae, Staphylococcus aureus,* or *Haemophilus influenzae*. When suspected, the influenza virus can be detected using a rapid antigen detection assay, which can distinguish influenza A from B. Antiviral therapy against influenza A (e.g., amantadine, rimantadine, oseltamivir, or zanamivir) or influenza B (e.g., oseltamivir or zanamivir) is recommended if started within 48 hours of symptom onset. Specific antiviral therapy does not exist against parainfluenza, respiratory syncytial virus, adenovirus, metapneumovirus, coronavirus (severe acute respiratory syndrome agent), or hantavirus. Management of these infections involves supportive care and vigilant infection control measures.

13. Which patients with severe CAP and acute respiratory failure benefit from noninvasive positive pressure ventilation (NPPV)? {#s0130}
-------------------------------------------------------------------------------------------------------------------------------

Clinical trials have demonstrated that the use of NPPV for acute respiratory failure from severe CAP can reduce the need for intubation and decrease mortality in patients with COPD or immunocompromised states. Patients must be suitable candidates for NPPV based on current practice guidelines. There is no evidence to support the use of NPPV in immunocompetent patients who do not have COPD but do have severe CAP.

14. What is health care--associated pneumonia (HCAP)? {#s0140}
-----------------------------------------------------

The term *HCAP* refers to pneumonia that develops in a patient who lives in a nursing home or long-term care facility; undergoes hemodialysis; has received IV antimicrobial therapy, chemotherapy, or wound care within the preceding 30 days; or has been hospitalized for at least 2 days within the preceding 90 days. The causative pathogens in these patients are similar to those responsible for hospital-acquired pneumonia and ventilator-associated pneumonia (VAP) and are often multidrug resistant.

15. Summarize the pathogenesis of VAP. {#s0150}
--------------------------------------

The majority of cases are due to microaspiration of pathogens colonizing the oropharynx. Endotracheal intubation interferes with normal host defenses by impairing the patient\'s ability to cough and disrupting the protective barrier between the oropharynx and trachea. Bacteria-laden oropharyngeal secretions pool and leak around the cuff of the endotracheal tube and infect the lower respiratory tract. This is facilitated when the patient is supine. It has been hypothesized that the endotracheal tube is colonized with bacteria encased in biofilm and that tube manipulation or suctioning results in embolization of bacteria into the lower respiratory tract. Other less common sources of bacteria include the paranasal sinuses, dental plaque, gastrointestinal tract, and rarely hematogenous spread from another site of infection.

Chastre J: Conference Summary: Ventilator-associated pneumonia. Respir Care 50:975--983, 2005.

16. List the most common pathogens responsible for VAP. {#s0160}
-------------------------------------------------------

The most common causative organisms are listed in [Table 17-2](#t0020){ref-type="table"} . The relative frequency of these pathogens and their respective resistance patterns vary depending on the institution, prior exposure to antibiotics, host factors, and the duration of mechanical ventilation. Clinicians should be familiar with their institution\'s spectrum of common nosocomial pathogens and current resistance patterns.Table 17-2Etiologic Pathogens That Cause Ventilator-Associated Pneumonia*Pseudomonas aeruginosaStaphylococcus aureus*Enterobacteriaceae▪ *Klebsiella* species▪ *Escherichia coli*▪ *Proteus* species▪ *Enterobacter* species▪ *Serratia* species▪ *Citrobacter* species*Acinetobacter* spp.*Stenotrophomonas maltophiliaHaemophilus influenzaeLegionella pneumophilaStreptococcus* speciesCoagulase-negative staphylococci*Neisseria* speciesAnaerobes[^7][^8]

17. What are the diagnostic criteria for VAP? {#s0170}
---------------------------------------------

Universally agreed-upon diagnostic criteria for VAP do not exist; however, commonly used criteria include the presence of *all* of the following:1Mechanical ventilation for \>48 hours2A new and persistent infiltrate on chest radiograph or ARDS (in the setting of ARDS, it may be impossible to visualize a new infiltrate on chest radiograph)3Two of the following three findings:▪Fever (temperature \>38°C)▪Leukocytosis or leukopenia▪Purulent tracheal secretions4Quantitative bacterial cultures of a lower respiratory tract specimen at or above the threshold defined as consistent with lung infection

The use of clinical criteria alone without microbiologic data tends to lead to overdiagnosis of lung infection.

18. Discuss the differences between qualitative and quantitative bacterial cultures of endotracheal aspirates from patients suspected of VAP. {#s0180}
---------------------------------------------------------------------------------------------------------------------------------------------

Colonization of the endotracheal tube occurs within 5 days of mechanical ventilation and, thus, qualitative cultures of endotracheal aspirates rarely yield negative results. Qualitative cultures are sufficiently sensitive (82%) to identify the infecting pathogen but lack specificity (27%). Therefore, quantitative cultures are necessary to distinguish oropharyngeal contaminants from infection. The recommended threshold for quantitative cultures of endotracheal aspirates ranges from 10^5^ to 10^6^ colony-forming units (CFU)/mL. Unless antibiotic therapy has been started or adjusted within the preceding 72 hours, *sterile* cultures from endotracheal aspirates have a strong negative predictive value (94%).

Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867--903, 2002.

19. What are the various invasive methods for obtaining lower respiratory tract specimens for quantitative cultures? {#s0190}
--------------------------------------------------------------------------------------------------------------------

Bronchoscopic methods include bronchoalveolar lavage and protected specimen brush. Nonbronchoscopic methods can be performed in intubated patients by respiratory therapists and include minibronchoalveolar lavage and protected telescoping catheter. Bronchoscopic and nonbronchoscopic methods have similar performance characteristics; however, the diagnostic threshold for each procedure varies. Although nonbronchoscopic procedures are performed blindly and most frequently sample the right lower lobe, studies have shown that VAP is a diffuse process that typically involves every pulmonary lobe, particularly the posterior lower lobes.

20. What are the advantages of quantitative cultures of lower respiratory tract specimens over a clinical approach for the diagnosis of VAP? {#s0200}
--------------------------------------------------------------------------------------------------------------------------------------------

A microbiologic diagnosis using quantitative cultures of lower respiratory tract specimens not only establishes the presence of lung infection, but also identifies the etiologic organism. Several studies have shown that unless antibiotic therapy was initiated or changed within 72 hours preceding sampling, antibiotics can be safely discontinued when quantitative cultures of lavage specimens are below the diagnostic threshold. Qualitative or semiquantitative cultures of the trachea rarely yield negative results due to tracheal colonization even in the absence of lung infection.

A multicenter, randomized, controlled trial of over 400 patients meeting clinical criteria for VAP showed that a diagnostic strategy involving bronchoscopic sampling and quantitative cultures resulted in significantly less antibiotic use and decreased 14-day mortality when compared with a clinical diagnostic strategy using qualitative cultures of endotracheal aspirates.

Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 132:621--630, 2000.

21. Are there factors that predispose patients to nosocomial lung infection with drug-resistant organisms? {#s0210}
----------------------------------------------------------------------------------------------------------

Hospital-acquired pneumonia (HAP) or VAP that develops within the first 4 hospital days is described as *early-onset.* A patient is at risk for infection with drug-resistant pathogens when HAP or VAP develops ≥5 days of hospitalization (i.e., *late-onset*) or if, within the preceding 3 months, the patient was hospitalized or received antibiotics. Additional risk factors for multidrug-resistant pathogens are listed in [Table 17-3](#t0030){ref-type="table"} and should be considered when prescribing empiric therapy for nosocomial pneumonia.Table 17-3Risk Factors for Multidrug-Resistant Pathogens Causing Hospital-Acquired Pneumonia, HealthCare-Associated Pneumonia, and Ventilator-Associated Pneumonia▪ Antimicrobial therapy in preceding 90 days▪ Current hospitalization of 5 days or more▪ High frequency of antibiotic resistance in the community or in the specific hospital unit▪ Presence of risk factors for HCAP: □ Hospitalization for 2 days or more in the preceding 90 days □ Residence in a nursing home or extended care facility □ Home infusion therapy (including antibiotics) □ Chronic dialysis within 30 days □ Home wound care □ Family member with multidrug-resistant pathogen▪ Immunosuppressive disease and/or therapyData from American Thoracic Society; Infections Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care--associated pneumonia. Am J Respir Crit Care Med 171:388--416, 2005, with permission.

22. What determines the selection of the initial empiric antibiotic therapy for HAP, HCAP, and VAP? {#s0220}
---------------------------------------------------------------------------------------------------

Investigations have shown that early, appropriate (meaning, effective against the etiologic pathogen) antimicrobial therapy for VAP improves outcomes. The ATS guidelines recommend empiric therapy. The initial selection of antibiotics depends on whether the patient has risk factors for drug-resistant nosocomial pathogens and whether the pneumonia is classified as early- or late-onset. Individual institutions differ in patterns of antimicrobial resistance; therefore, many hospitals have antibiotic guidelines or antibiograms for empiric therapy based on likely pathogens and local antimicrobial resistance patterns. If the patient has received antibiotics recently, empiric therapy should include antimicrobials from a different class than the patient received ([Table 17-4](#t0040){ref-type="table"}, [Table 17-5](#t0050){ref-type="table"} ).Table 17-4Initial Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia or Ventilator-Associated Pneumonia in Patients with no Known Risk Factors for Multidrug-Resistant Pathogens, Early Onset, and Any Disease SeverityPotential PathogenRecommended Antibiotic*Streptococcus pneumoniae*[\*](#tn0070){ref-type="table-fn"}Ceftriaxone*Haemophilus Influenzaeor*Methicillin-sensitive *Staphylococcus aureus*Levofloxacin, moxifloxacin, or ciprofloxacinAntibiotic-sensitive enteric gram-negative bacilli*or* *Escherichia coli*Ampicillin/sulbactam *Klebsiella pneumoniaeor* *Enterobacter* speciesErtapenem *Proteus* species *Serratia marcescens*[^9]Data from American Thoracic Society; Infections Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care--associated pneumonia. Am J Respir Crit Care Med 171:388--416, 2005, with permission.Table 17-5Initial Empiric therapy for Hospital-acquired pneumonia. Ventilator-associated pneumonia, and Health Care--associated Pneumonia in patients with late-onset disease or risk factors for Multidrug-Resistant pathogens and all Disease SeverityPotential PathogensCombination Antibiotic Therapy[\*](#tn0080){ref-type="table-fn"}Pathogens listed in [Table 17-4](#t0040){ref-type="table"} and MDR pathogensAntipseudomonal cephalosporin (cefepime, ceftazidime) *Pseudomonas aeruginosaorKlebsiella pneumoniae* (ESBL +)[†](#tn0090){ref-type="table-fn"}Antipseudomonal carbepenem (imipenem or meropenem)*Acinetobacter* species[†](#tn0100){ref-type="table-fn"}*or*β-Lactam/β-lactamase inhibitor (piperacillin--tazobactam)*plus*Antipseudomonal fluoroquinolone[† (ciprofloxacin or levofloxacin)](#tn0100){ref-type="table-fn"}*or*Aminoglycoside (amikacin, gentamicin, or tobramycin)*plus* Methicillin-resistant *Staphylococcus aureus* (MRSA)Linezolid or vancomycin[‡](#tn0100){ref-type="table-fn"}*Legionella pneumophila*[†](#tn0100){ref-type="table-fn"}[^10][^11][^12]

23. What is the duration of antimicrobial therapy for HAP, HCAP, and VAP? {#s0230}
-------------------------------------------------------------------------

In a prospective, randomized clinical trial, an 8-day treatment strategy for culture-proven VAP resulted in a significant decrease in multidrug-resistant bacteria and more antibiotic-free days with no differences in mortality, ICU length of stay, or mechanical ventilator--free days compared with a 15-day regimen. A higher rate of recurrence was documented with the 8-day regimen when the infection was due to *Acinetobacter* or *Pseudomonas* species; therefore, VAP due to these organisms should be treated for 15 days. Because the infecting pathogens are similar, HAP and HCAP can be treated similarly. Extended therapy (14--21 days) may be indicated in the setting of multilobar disease, cavitation, malnutrition, or necrotizing gram-negative infection.

Chastre J, Wolff M, Fagon J-Y, et al: Comparison of 8 to 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 290:2588--2598, 2003.

24. Describe measures that can decrease the risk of VAP. {#s0240}
--------------------------------------------------------

1Avoid intubation when possible, and apply NPPV when appropriate.2Consider orotracheal tubes preferentially over nasotracheal tubes.3Minimize the duration of mechanical ventilation with the aid of weaning protocols.4Apply continuous aspiration of subglottic secretions.5Maintain an endotracheal tube cuff pressure \>20 cm H~2~O to prevent leakage of oropharyngeal secretions containing bacteria into the lungs.6Avoid unnecessary manipulation of the ventilator circuit.7Carefully discard contaminated condensate from the ventilator circuit.8Keep the head of the bed elevated 30 degrees.9Avoid heavy sedation and paralytics because they impair the patient\'s ability to cough.10It does not appear that sucralfate or therapies that decrease gastric acid increase the incidence of nosocomial pneumonia.

Cook D, Guyatt G, Marsahall J, et al: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 338:791--797, 1998.

Mallow S, Rebuck JA, Osler T, et al: Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 61:452--458, 2004.

Messori A, Trippoli S, Vaiani M, et al: Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: Meta-analysis of randomized controlled trials. BMJ 321:1--7, 2000.

25. Under what circumstances is a thoracentesis indicated for a parapneumonic effusion? {#s0250}
---------------------------------------------------------------------------------------

If the patient is clinically stable and a thoracentesis can be performed safely, then significant (\>10 mm on lateral decubitus film) or loculated pleural effusions should be sampled whenever a complicated parapneumonic effusion (persistent bacterial invasion of the pleural space) or an empyema (frank pus in the pleural space) is suspected. Thoracentesis is also indicated when the diagnosis is elusive and the patient\'s condition is not responding favorably to empiric antibiotic therapy. Pleural fluid should be analyzed for cell count and differential, protein, glucose, lactate dehydrogenase (LDH), Gram\'s stain, acid-fast stain, and cultures for bacteria, fungi, and mycobacteria. Drainage is required for complicated parapneumonic effusions and empyemas.Websites1American Thoracic Society [www.thoracic.org](http://www.thoracic.org){#ir0005}2Infectious Diseases Society of America [www.idsociety.org](http://www.idsociety.org){#ir0010}

[^1]: Excludes patients at risk for HIV.

[^2]: In roughly one-third to one-half of the cases no etilogy was identified.

[^3]: In no particular order.

[^4]: Antipseudomonal agents such as cefepime, piperacillin/tazobactam, imipenem, and meropenem are generally active against DRSP and other likely pathogens in this population, but not recommended for routine use unless the patient has risk factors for *P. aeruginosa.*

[^5]: Combination therapy required.

[^6]: If β-lactam allergic, replace the listed β-lactam with aztreonam and combine with an aminoglycoside and an antipneumococcal fluoroquinolone as listed.

[^7]: Polymicrobial infection (particularly common in ARDS).

[^8]: ARDS = acute respiratory distress syndrome.

[^9]: The frequency of penicillin-resistant *S. pneumoniae* and multidrug-resistant *S. pneumoniae* is increasing; levofloxacin or moxiflox-acin are preferred to ciprofloxacin and the role of other new quinolones, such as gatifloxacin, has not been established.

[^10]: Initial antibiotic therapy should be adjusted or streamlined on the basis of microbiologic data and clinical response to therapy.

[^11]: If an ESBL + strain, such as *K. pneumoniae*, or an *Acinetobacter* species is suspected, a carbepenem is a reliable choice. If *L. pneumophila* is suspected, the combination antibiotic regimen should include a macolide (e.g., azithromycin) or a fluoroquinolone (e.g., ciprofloxacin or levofloxacin) should be used ratherthan an aminoglycoside.

[^12]: If MRSA risk factors are present or there is a high incidence locally.
